Deadline AlertLast Reviewed: May 2026CM-INS-089 // May 2026
NIH R01 Clinical Trial Deadline Approaching: June 2026 Application Guide for Investigators
The R01 is the currency of academic clinical research — it's what separates an investigator who's "running a trial" from one who's actually funded to do it properly. The June 2026 cycle operates under the same payline pressures as every cycle in recent years, but the clinical trial-specific requirements have grown substantially more burdensome since NIH tightened its definition of what constitutes a "clinical trial" in 2017. If you haven't done a clinical trial R01 recently, the Human Subjects sections alone will surprise you. This guide covers the June 5, 2026 deadline specifically — payline context, the CTR designation trap that kills applications at intake, and what study sections consistently criticize in clinical trial submissions.
Research Funding Notice
This article is for research investigators and institutional administrators. It does not constitute legal or regulatory advice. Verify all requirements with your institution's Office of Research and the NIH program officer for your specific application.
⚠
Deadline Alert
NIH R01 standard due date for new applications: June 5, 2026. Clinical trial R01s require additional lead time — IND/IDE status, IRB approval plan, and DSMB arrangements must all be addressed in the application. Start Human Subjects sections now.
Summary
The R01 Research Project Grant funds the overwhelming majority of investigator-initiated clinical trials at NIH — Phase I through Phase III, plus observational research involving human participants. Clinical trial R01s use the same June 5, 2026 standard deadline as basic science applications, but the complexity is categorically different. You're not just writing a Research Strategy; you're simultaneously building a regulatory compliance framework, a recruitment feasibility case, and a safety monitoring plan — all of which require institutional coordination that basic science investigators simply don't face. Three to four weeks minimum for Human Subjects alone. Start now.
ClinicalMetric Analysis
The CTR designation problem is the most common preventable intake failure for clinical trial applications — and it's fixed with a 15-minute Program Officer call before you choose your FOA, not after you've written 25 pages. NIH's clinical trial definition is broader than most investigators assume: if you have human participants, you're assigning an intervention, and you're measuring a health-related biomedical or behavioral outcome, NIH almost certainly classifies it as a clinical trial. The Clinical Trial Decision Tool at grants.nih.gov helps but isn't definitive for ambiguous study designs. The PO call is the authoritative step — and it takes less time than revising a full application after administrative rejection.
Power calculations derived from a single small pilot study are the most consistently flagged weakness in clinical trial R01 study section reviews — and inflate-adjusted sensitivity analyses are now expected, not optional. Small pilot studies produce effect size estimates that are systematically inflated relative to what will be observed in a fully powered trial. Study sections know this. The appropriate response is to show power under your pilot effect size AND under a 30% smaller effect — demonstrating that the trial is powered to detect a clinically meaningful difference even if your pilot was optimistic. Reviewers who see only the pilot-anchored power calculation without sensitivity analysis will flag it; reviewers who see both will not. This is a 2-paragraph addition to the Research Strategy that eliminates a common fatal weakness.
DSMB plans in R01 applications are routinely scored as vague because applicants devote 3 sentences to a section that reviewers expect 1–2 pages on — and the specific elements that satisfy reviewers are predictable. A complete DSMB plan includes: prospective member qualifications (biostatistician, clinical expert in the disease area, patient advocate) ideally with named individuals, monitoring schedule tied to enrollment milestones (e.g., after every 25% of subjects enrolled), safety stopping rules with explicit severity thresholds, and the specific statistical boundary for efficacy interim analyses (O'Brien-Fleming, Lan-DeMets alpha spending function) with the alpha allocated to each interim. Phase 2 trials need this as much as Phase 3. "We will establish a DSMB with appropriate expertise and hold meetings as needed" is the response that generates a reviewer comment. The specificity that eliminates it is achievable in 400 words.
The CTR Designation Problem That Kills Applications at Intake
Here's where investigators get in trouble before a single reviewer reads their science. NIH defines a clinical trial in a way that is broader than most investigators assume — it's not just randomized controlled trials. If your study involves human participants, you're assigning an intervention, and you're measuring a health-related biomedical or behavioral outcome, NIH almost certainly classifies it as a clinical trial. Submitting that application to a "Clinical Trial Not Allowed" (CTNA) FOA gets it rejected without review. Doesn't matter how good the science is.
The Clinical Trial Requirement (CTR) designation must match the FOA you choose. Use NIH's Clinical Trial Decision Tool at grants.nih.gov before you pick your FOA — not after you've written 25 pages of Significance and Innovation. Contact the Program Officer for the relevant Institute and confirm your study meets their specific FOA requirements. This conversation takes fifteen minutes and can save months of work on a misdirected application.
What Study Sections Actually Score on Clinical Trial R01s
Having reviewed study section critiques across multiple cycles, the patterns are consistent. Reviewers are not simply evaluating whether the science is interesting — they're evaluating whether this specific team can actually execute this specific trial. Those are different questions, and many applications conflate them.
Recruitment feasibility is the most common fatal weakness. Saying you have access to a clinic with 3,000 patients with the relevant condition is not enough. Reviewers want documented referral relationships, site experience in trial enrollment, and a realistic accrual projection — with monthly numbers, not just total sample size. If you've run a prior study at that site, cite your actual enrollment rates. If you haven't, explain who has and why they're co-investigators.
Power calculations need to be clinically anchored. A power calculation derived from a single small pilot study will get flagged. Reviewers want to see the MCID (Minimum Clinically Important Difference) for your primary endpoint, justified from the literature, and a sample size calculation that would survive if your pilot effect size was inflated by 30%. Inflate-adjusted sensitivity analyses are now expected in most study sections.
DSMB plans that lack specifics. "We will establish a DSMB" is not a DSMB plan. Name potential members, specify the monitoring schedule, define the stopping rules for safety and futility, and describe the statistical boundaries (O'Brien-Fleming, Lan-DeMets, etc.) you'll use for interim analyses. Phase II trials need this as much as Phase III.
Team qualifications under scrutiny. Does the PI have a track record of completed trials? Is there a dedicated biostatistician with trial experience — not just someone who "can analyze data"? Is there clinical research coordinator infrastructure that has enrolled human subjects before? Reviewers check CVs for trial execution history, not just publication lists.
IND/IDE ambiguity. Applications that say "we will determine if an IND is needed" rather than demonstrating they've already worked through this question are asking for a concern. FDA pre-IND meetings take 2–3 months to schedule; reviewers know this timeline and will note if your application doesn't reflect it.
Required Sections Unique to Clinical Trial R01s
Protection of Human Subjects: For a clinical trial, this section is substantive — IRB approval status or plan, recruitment and consent procedures, assessment of risks and benefits, data confidentiality measures, and special population protections if applicable. Budget three to four weeks minimum.
Inclusion of Women, Minorities, and Children: Enrollment plans must be justified or demonstrate compliance with NIH's inclusion policies. Exclusion of any group requires scientific justification — reviewers are increasingly skeptical of convenience-based exclusions that result in homogeneous trial populations.
Data Safety Monitoring Plan: Phase II and III trials require a full DSMB plan. Phase I trials require at minimum a description of stopping rules and safety review procedures. The DSMP must specify who makes safety decisions and on what timeline.
Single IRB designation: Multi-site trials funded by NIH after January 2020 must use a single IRB of record. This requires institutional agreement and coordination before submission — it cannot be retroactively established after award.
Dissemination Plan: Clinical trial R01s require a plan for disseminating results, including ClinicalTrials.gov reporting timelines. NIH has been increasingly enforcing reporting requirements; the dissemination plan is reviewed as part of the application, not just noted as a checkbox.
Timeline: What to Be Doing Right Now
Immediately: Confirm your study's clinical trial status using the NIH Decision Tool. Contact the IC Program Officer. Identify your FOA and confirm it's still open for the June cycle.
Now through mid-April: Begin Human Subjects sections. Initiate IRB pre-submission contact if IRB approval isn't already in hand. Confirm IND/IDE status with institutional regulatory affairs. Identify DSMB candidates.
April through mid-May: Draft and iterate Research Strategy with study section-specific critique in mind. Complete power and sample size sections with clinical anchoring. Write DSMB and DSMP in detail.
Late May: Submit to your institution's grants office for sign-off — budget five to seven business days for institutional review. Large clinical trial applications generate substantial administrative complexity; coordinate early.
June 5, 2026: Submission deadline. Confirm receipt in eRA Commons within 48 hours. Any system issues must be reported to NIH on the day they occur.
Key Deadlines
June 5, 2026 — New R01 standard due date (Clinical Trial Required)
July 5, 2026 — A1 resubmission due date
~October 2026 — Study Section review meetings for June submissions
~December 2026 — Summary Statements released for June submissions
October 5, 2026 — Next new R01 standard due date
Frequently Asked Questions
What is an NIH R01 and how does it support clinical trials?
The R01 is the NIH research project grant — the primary mechanism for investigator-initiated research funding. For clinical trials, NIH designates applications as "Clinical Trial Required" (CTR), "Clinical Trial Optional" (CTO), or "Clinical Trial Not Allowed" depending on the funding opportunity announcement (FOA). CTR R01s specifically require a clinical trial component as defined by NIH: a research study involving human participants in which the investigator designs the study, collects data, and directly manipulates variables. Most intervention studies, drug trials, and device trials qualify. Important: many behavioral and health services studies that previously weren't considered "clinical trials" now fall under NIH's expanded definition, requiring DSMB and additional oversight documentation.
What additional requirements apply to NIH R01 clinical trials vs. basic research grants?
NIH CTR applications require: Human Subjects sections that are more detailed than observational research applications; a Data Safety Monitoring Plan (DSMP) or an independent Data Safety Monitoring Board (DSMB) for Phase 2/3 trials or certain Phase 1 designs; IND/IDE information if applicable; detailed clinical trial registration plan (ClinicalTrials.gov registration before first enrollment); sex/gender as biological variables (SABV) analysis plan; and a dissemination plan addressing results reporting. For trials involving INDs, institutional regulatory affairs contact should be established before submission. Reviewers in CTR study sections are experienced in evaluating these requirements — underdeveloped DSMB/DSMP sections are among the most cited weaknesses in unsuccessful applications.
What is the difference between a CTR, CTO, and CTNA funding opportunity?
FOAs are designated by NIH as: Clinical Trial Required (CTR) — must include a clinical trial component as defined by NIH; Clinical Trial Optional (CTO) — may include a clinical trial but does not require one; Clinical Trial Not Allowed (CTNA) — explicitly prohibits clinical trial components. Applications submitted to the wrong FOA category (e.g., a clinical trial application submitted to a CTNA FOA) are administratively rejected without review. This distinction matters because CTR and CTNA FOAs have different study section assignments, different review criteria weights, and different submission deadlines. Confirming your study's classification and matching it to the correct FOA is a fundamental first step before R01 preparation.
What are the most common reasons NIH clinical trial R01 applications are not funded?
Reviewers consistently cite: insufficient statistical power justification (sample size calculations not anchored to a clinically meaningful effect size from the literature); underdeveloped eligibility criteria that are either too restrictive to enroll feasibly or too broad to test the hypothesis; DSMB/DSMP sections that lack specificity about what events will trigger review and what stopping rules apply; lack of pilot data supporting the feasibility and expected effect size; and investigator team gaps in clinical trial conduct experience for the proposed scale. Applications that treat the CTR as a regulatory checkbox rather than a central scientific component consistently score lower than applications where the trial design is the scientific centerpiece.
B.Sc. Agricultural Sciences. ISO inspector and compliance auditor. Researches and writes ClinicalMetric Insights using primary sources: ClinicalTrials.gov, FDA, EudraCT, PubMed.
Physiotherapy student. Reviews Insights articles for medical accuracy and patient relevance — condition descriptions, eligibility language, and treatment context for patients and caregivers.
B.Sc. Informatics & Communications (in progress). Responsible for ClinicalMetric's technical architecture, API integrations with ClinicalTrials.gov, and data accuracy verification.
🔄 Trial data updated daily from ClinicalTrials.gov
◆ Editorial & Research Standards
Stage 1 — Primary Research
ClinicalTrials.gov registry data (NIH/NLM), FDA documentation, EudraCT, and peer-reviewed literature. Trial status, phase, eligibility, and enrollment data verified at source.
Stage 2 — Medical Accuracy Review
Cross-checked against PubMed/MEDLINE literature and FDA/EMA communications. Eligibility criteria and patient safety information verified for accuracy.
Stage 3 — Registry Verification
Phase classification, enrollment status, sponsor identity, and trial location cross-referenced against official registry records before publication.
⚕️ Medical Disclaimer: ClinicalMetric provides research intelligence only. Always consult a qualified healthcare provider before making clinical decisions or participating in a trial.
Publisher
ClinicalMetric
Independent Clinical Trial Intelligence
Tracks 400,000+ active clinical trials worldwide. Updated daily from ClinicalTrials.gov (NIH/NLM), FDA IND registry, and EudraCT (EU Clinical Trials Register).
Research Methodology
Articles are researched from primary registry sources: ClinicalTrials.gov XML feeds, FDA trial databases, and peer-reviewed literature. Trial status, phase, enrollment, and eligibility data is sourced directly from registry APIs — not secondary aggregators.
Trial status, enrollment, and eligibility information changes frequently. ClinicalMetric syncs with ClinicalTrials.gov daily. Editorial articles are reviewed quarterly or when major protocol amendments are published. Always verify trial status directly on ClinicalTrials.gov before making clinical decisions.
◆ Live Clinical Trial Feed
Browse 400,000+ Active Clinical Trials
Updated daily from ClinicalTrials.gov · Recruiting trials by condition, phase, sponsor
Editorial Notice: This article was reviewed by the ClinicalMetric editorial team. Clinical trial data changes frequently as trials progress, enroll, or close. Nothing on this site constitutes medical advice — always consult a qualified healthcare professional. To report an inaccuracy, contact dev@clinicalmetric.com.
Clinical Trial Research & Analysis · Last updated April 2026
Analysis compiled from ClinicalTrials.gov (NIH/NLM), FDA trial registry data, and peer-reviewed clinical research. ClinicalMetric tracks 400,000+ active clinical trials worldwide, updated daily from the ClinicalTrials.gov AACT database.
Get Weekly Clinical Trial Alerts
New recruiting trials from NIH, NCI, and 40+ sponsors — every Monday. Free forever.
✓ You're on the list!
◆ Clinical Trial Intelligence at a Glance
400K+
Active trials tracked
200+
Countries with active trials
4
Clinical trial phases
Daily
Data refresh from ClinicalTrials.gov
◆ Clinical Trial Phase Transition Success Rates
Phase 1 → Phase 2 success~63%
Phase 2 → Phase 3 success~32%
Phase 3 → Approval~58%
Overall FDA approval rate~12%
Source: Biotechnology Innovation Organization (BIO) Clinical Development Success Rates — approximate industry averages.
◆ Clinical Trial Development Timeline
Mo 1–6
Preclinical + IND Filing
Mo 6–18
Phase 1 (Safety)
Mo 18–48
Phase 2 (Efficacy)
Mo 48–84
Phase 3 (Pivotal)
Mo 84–96
FDA Review / NDA
Mo 96+
Approval + Phase 4
Timeline is approximate. Total development from preclinical to approval averages 6–13 years.
Our analysts monitor 400,000+ clinical trials daily across oncology, neurology, cardiology, and rare diseases. All data sourced from ClinicalTrials.gov and FDA.gov.
🔬 400K+ trials tracked🌍 200+ countries🔄 Updated: July 2026
◆ Common Questions About Clinical Trials
What is a clinical trial?
+
A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).
How do I find clinical trials I'm eligible for?
+
You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.
Are clinical trials safe to participate in?
+
Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.
What are the phases of clinical trials?
+
Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.
Do participants get paid for joining clinical trials?
+
Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology
We use cookies to analyze site traffic and improve your experience. By clicking "Accept", you consent to our use of cookies as described in our Privacy Policy.
◆ Free Clinical Trial Alerts
Get Weekly Clinical Trial Alerts
New recruiting trials from NIH, NCI, and 40+ sponsors — every Monday. Free.